大黄虫丸联合阿德福韦酯抗慢性乙型肝炎肝纤维化的实验研究

目的:探讨大黄虫丸联合阿德福韦酯抗慢性乙型肝炎肝纤维化的实验指标变化。方法:94例慢性乙肝患者,随机分为治疗组50例与对照组44例:治疗组用阿德福韦酯10 mg/次,每日口服1次,联合大黄虫丸每次1丸,每日口服3次;对照组单用阿德福韦酯,疗程6个月。结果:治疗组肝纤维化指标比治疗前明显降低(P<0.01),与对照组比差异有显著性(P<0.01或P<0.05);治疗组治疗后血清ALT,AST,GGT,TBIL等指标与治疗前相比显著减低(P<0.01),与对照组比差异有显著性(P<0.01)。结论:大黄虫丸联合阿德福韦酯可控制慢性乙肝纤维化,缓解、降低肝硬化发生率,改善预后,提高患者生存质量。

Experimental study on effect of Dahuang Zhechong Wan combined with adefovir dipivoxil in preventing hepatic fibrosis in patients with chronic hepatitis B

Objective: To study the changes of experimental markers of hepatic fibrosis in patients with chronic hepatitis B treated by Dahuang Zhechong Wan combined with adefovir dipivoxil. Method: ninty and four cases of chronic viral hepatitis B patients were randomly divided into two groups. The treatment group (50 cases) was orally given 10 mg of adefovir dipivoxil once a day, 1 Wan each time, combined with Dahuang Zhechong Wan, 3 times a day, 1 Wan each time. And the control group (44 cases) was treated with adefovir dipivoxil alone, 6 months as a course. Result: Both the difference of liver fibrosis indexes between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P<0.01 or P<0.05). Both the difference of experimental markers such as ALT, AST, GGT, TBIL between the treatment group and the control group and before and after the treatment in the treatment group had statistical significance (P<0.01). Conclusion: Dahuang Zhechong Wan combined with adefovir dipivoxil could prevent hepatic fibrosis in patients with chronic hepatitis B, reduce the incidence of liver cirrhosis, improve life quality and prognosis.